Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2PFI8
|
|||
| Drug Name |
SAR445136
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 1 | [1] | |
| Company |
Sanofi Bridgewater, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05145062) An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.